EA201990512A1 - АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ КЛЕТОК КРОВИ - Google Patents

АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ КЛЕТОК КРОВИ

Info

Publication number
EA201990512A1
EA201990512A1 EA201990512A EA201990512A EA201990512A1 EA 201990512 A1 EA201990512 A1 EA 201990512A1 EA 201990512 A EA201990512 A EA 201990512A EA 201990512 A EA201990512 A EA 201990512A EA 201990512 A1 EA201990512 A1 EA 201990512A1
Authority
EA
Eurasian Patent Office
Prior art keywords
blood cells
malignant tumors
treatment
pparγ agonist
pparγ
Prior art date
Application number
EA201990512A
Other languages
English (en)
Russian (ru)
Inventor
Кристос Мантзорос
Original Assignee
Интекрин Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Интекрин Терапьютикс, Инк. filed Critical Интекрин Терапьютикс, Инк.
Publication of EA201990512A1 publication Critical patent/EA201990512A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA201990512A 2016-08-18 2017-08-18 АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ КЛЕТОК КРОВИ EA201990512A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662376749P 2016-08-18 2016-08-18
PCT/US2017/047578 WO2018035446A1 (en) 2016-08-18 2017-08-18 PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS

Publications (1)

Publication Number Publication Date
EA201990512A1 true EA201990512A1 (ru) 2019-08-30

Family

ID=61197183

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990512A EA201990512A1 (ru) 2016-08-18 2017-08-18 АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ КЛЕТОК КРОВИ

Country Status (12)

Country Link
US (1) US20210379049A1 (https=)
EP (1) EP3500268A4 (https=)
JP (2) JP2019524888A (https=)
KR (1) KR20190064573A (https=)
CN (1) CN110461329A (https=)
AU (1) AU2017313839A1 (https=)
BR (1) BR112019003130A2 (https=)
CA (1) CA3034258A1 (https=)
EA (1) EA201990512A1 (https=)
MX (1) MX2019001979A (https=)
SG (2) SG11201901320WA (https=)
WO (1) WO2018035446A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201791982A1 (ru) 2015-03-09 2020-02-17 Интекрин Терапьютикс, Инк. Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy
WO2020243058A1 (en) * 2019-05-30 2020-12-03 Coherus Biosciences, Inc. Compositions and methods to treat cancer
JP2022104747A (ja) * 2020-12-29 2022-07-11 国立研究開発法人国立がん研究センター 抗ウイルス剤
JP2022104746A (ja) * 2020-12-29 2022-07-11 国立研究開発法人国立がん研究センター 抗がん剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3018186B1 (ja) * 1999-03-09 2000-03-13 大阪大学長 抗炎症剤、単球系細胞の増殖抑制剤
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
JP2010265216A (ja) * 2009-05-14 2010-11-25 Takeda Chem Ind Ltd 複素環化合物
KR102056756B1 (ko) * 2013-01-30 2019-12-17 인테크린 테라퓨틱스, 아이엔씨. 다발성 경화증의 치료를 위한 PPARγ 작용제
ES2866883T3 (es) * 2016-06-08 2021-10-20 Support Venture Gmbh Combinaciones farmacéuticas para el tratamiento del cáncer

Also Published As

Publication number Publication date
EP3500268A4 (en) 2020-04-15
CA3034258A1 (en) 2018-02-22
JP2019524888A (ja) 2019-09-05
KR20190064573A (ko) 2019-06-10
AU2017313839A1 (en) 2019-03-07
BR112019003130A2 (pt) 2019-05-21
CN110461329A (zh) 2019-11-15
US20210379049A1 (en) 2021-12-09
MX2019001979A (es) 2019-09-19
SG10202101501PA (en) 2021-03-30
JP2022116304A (ja) 2022-08-09
SG11201901320WA (en) 2019-03-28
WO2018035446A1 (en) 2018-02-22
EP3500268A1 (en) 2019-06-26

Similar Documents

Publication Publication Date Title
BR112023017763A2 (pt) Inibidores kras g12d
MX2023000410A (es) Analogos de rapamicina como inhibidores de mtor.
EA201890730A1 (ru) Производные пиразолопиримидина в качестве ингибиторов btk для лечения злокачественного новообразования
EA201791390A1 (ru) Способ получения соединения диарилтиогидантоина
MX380907B (es) Compuestos útiles como inhibidores de cinasa.
PH12020500655A1 (en) Compounds
MX380092B (es) Tratamiento de la osteoartritis.
EP4635568A3 (en) Compounds, salts thereof and methods for treatment of diseases
EA201991197A1 (ru) БЕНЗИМИДАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ c-Kit
EA201990512A1 (ru) АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ КЛЕТОК КРОВИ
EA201690204A1 (ru) Соединения n,6-бис(арил или гетероарил)-1,3,5-триазин-2,4-диамина в качестве ингибиторов мутантов idh2 для лечения ракового заболевания
EA201591382A1 (ru) Ингибиторы гистондеметилаз
MY203303A (en) Compounds
EA201591889A1 (ru) 6-(5-гидрокси-1h-пиразол-1-ил)никотинамидные ингибиторы phd
BR112018001017A2 (pt) inibidores do receptor de fator-1 de estimulação de colônia (csf-1r)
EA201790779A1 (ru) Замещенные аминопуриновые соединения, их композиции и способы лечения с использованием таких соединений
EA201792287A1 (ru) Способы лечения рака
EA201591362A1 (ru) Соединения и способы лечения бактериальных инфекций
EA201791391A1 (ru) Способы получения соединения диарилтиогидантоин
EA201792096A2 (ru) РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА
EA201992360A1 (ru) Кристаллические формы (s)-афоксоланера
EA201690227A1 (ru) Азаиндольные соединения, их получение и способы их применения
EA201992302A1 (ru) Соединения, используемые в качестве ингибиторов alcat1
EA201792288A1 (ru) Способы лечения рака
EA201990513A1 (ru) АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ПОРАЖЕНИЙ КОСТЕЙ